ライフサイエンスコーパス: nosocomial

1 NoV infections in hospitalized patients were nosocomial.

2 Transmission was mostly nosocomial.

3 aureus is a leading cause of community- and nosocomial-acquired infections, with a propensity for bi

4 Nosocomial acquisition and transmission of vancomycin-re

5 le-genome sequencing was used to demonstrate nosocomial acquisition of antimicrobial-resistant sequen

6 gut-colonizing strain, which was preceded by nosocomial acquisition of the infecting isolate in half

7 However, nosocomial acquisition was still the primary source of s

8 inosa bacteremia were prior transplantation, nosocomial acquisition, and septic shock at onset.

9 the leading cause of community-acquired and nosocomial acute gastroenteritis.

10 to a lower exposure to secondary insults and nosocomial adverse events, increasing the opportunity of

11 eservoirs of VREfm are largely assumed to be nosocomial although there is a paucity of data on altern

12 hylococcus aureus is a leading cause of both nosocomial and community-acquired infection.

13 ution of NoV genotypes among inpatients with nosocomial and community-acquired NoV infections, respec

14 evasive factors contribute to the success of nosocomial and community-associated clonal lineages, aid

15 multidrug-resistant fungal pathogen causing nosocomial and invasive infections associated with high

16 trict-wide outbreaks, or both; but far fewer nosocomial and reported smaller outbreaks.

17 vors succumb later to persistent, recurrent, nosocomial, and secondary infections, many investigators

18 ifficile; C difficile), the leading cause of nosocomial antibiotic-associated colitis and diarrhea in

19 required due to the high recurrence rates of nosocomial antibiotic-associated diarrhea.

20 -producing anaerobe pathogen, and can induce nosocomial antibiotic-associated intestinal disease.

21 f whether pneumonia is community-acquired or nosocomial, as well as the age and immune status of the

22 f whether pneumonia is community-acquired or nosocomial, as well as the age and immune status of the

23 We focused on cases involving a major nosocomial-associated strain, L. pneumophila sequence ty

24 erinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus.

25 One of the the most dominant nosocomial bacteria, Methicillin Resistant Staphylococcu

26 sm for the neurologic sequelae consequent to nosocomial bacterial pneumonia.

27 ungal pathogen that has been associated with nosocomial bloodstream and deep wound infections causing

28 PVCs accounted for a mean of 6.3% and 23% of nosocomial BSIs and nosocomial catheter-related BSIs, re

29 ated the effects of asymptomatic carriers on nosocomial C difficile infections.

30 Two proven nosocomial cases of Legionella pneumonia occurred at the

31 to resolve the infection source in possible nosocomial cases, we aimed to determine whether whole-ge

32 mean of 6.3% and 23% of nosocomial BSIs and nosocomial catheter-related BSIs, respectively.

33 Nosocomial clones, including epidemic sequence type 258

34 orbidity and mortality rates associated with nosocomial Clostridium difficile-associated diarrhea (CD

35 sistent regarding their efficacy in reducing nosocomial complication rates.

36 ssociation between documentation cohorts and nosocomial complications.

37 whether checklist usage was associated with nosocomial complications; when documented, elements were

38 Clostridium difficile causes toxin-mediated nosocomial diarrhea and community-acquired infections; n

39 e is the most frequently identified cause of nosocomial diarrhea and has been associated with epidemi

40 idium difficile remains the leading cause of nosocomial diarrhea worldwide, which is largely consider

41 difficile is the leading cause of infectious nosocomial diarrhea.

42 t Clostridioides difficile, a major cause of nosocomial diarrheal disease, exhibits phenotypic hetero

43 tridium difficile infection (CDI) is a major nosocomial disease associated with significant morbidity

44 for the enhanced surveillance and control of nosocomial E. faecium transmission and infection.

45 tion of patients with health care-associated nosocomial endocarditis decreased (from 17.7% to 15.3%;

46 , and (iii) persistence in patients and in a nosocomial environment.

47 e an active reservoir of C. difficile in the nosocomial environment.

48 o rely on contact precautions for preventing nosocomial ESBL-EC transmission in nonepidemic settings,

49 Nosocomial EVD transmission risk may be lower than feare

50 Nosocomial fungal infections require a robust scientific

51 vasive candidiasis is one of the most common nosocomial fungal infections worldwide.

52 orovirus is a leading cause of worldwide and nosocomial gastroenteritis.

53 study primary outcome or incidence of common nosocomial gastrointestinal and respiratory tract infect

54 tify the contribution of opioid tampering to nosocomial HCV outbreaks, data from health care-related

55 Candida auris is a serious nosocomial health risk, with widespread outbreaks occurr

56 precision surveillance to delineate a large nosocomial IAV outbreak, mapping the source of the outbr

57 [95% CI, 1.07-1.32], P = .001); presence of nosocomial infection (OR = 36.3 [95% CI, 9.71-135.96], P

58 Invasive candidiasis (IC) is the most common nosocomial infection and a leading cause of mycoses-rela

59 ificantly greater in patients that developed nosocomial infection and organ dysfunction than similarl

60 eumoniae, which are frequently implicated in nosocomial infection and preterm infant gut colonization

61 hospital admission, discharge criteria, and nosocomial infection control.

62 [95% confidence interval {CI}, .30-.83]) and nosocomial infection empirically treated with imipenem o

63 lthcare settings, yet the greatest burden of nosocomial infection occurs in resource-restricted setti

64 Nosocomial infection was mainly associated with older ag

65 o delayed referral versus risk of death from nosocomial infection with severe acute respiratory syndr

66 d pharmaceutical industries to help minimize nosocomial infection, food spoilage, and pharmaceutical

67 coccus faecium (VREfm) is a leading cause of nosocomial infection.

68 r developing fecal carriage that may lead to nosocomial infection.

69 ated with levels of the type 2 cytokines and nosocomial infection.

70 e L. pneumophila population as the source of nosocomial infection.

71 hylococcus aureus (MRSA) is a major cause of nosocomial infection.

72 en, prominent in antimicrobial-resistant and nosocomial infection.

73 ated ventilator-associated complication were nosocomial infections (27.3% and 43.8%), including venti

74 that renders trauma patients susceptible to nosocomial infections (NI) and prolonged intensive care

75 CI, 0.68-1.90; I = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61

76 ference was found for the duration of common nosocomial infections [mean (range): 3.58 (1-7) vs. 3.79

77 esponsible for large numbers of postsurgical nosocomial infections across the United States and world

78 tridioides difficile is the leading cause of nosocomial infections and a worldwide urgent public heal

79 tant strains of this bacterium cause serious nosocomial infections and are the leading cause of death

80 unsaturated fatty acids on the prevalence of nosocomial infections and clinical outcomes in medical a

81 yunsaturated fatty acids reduces the risk of nosocomial infections and increases the predicted time f

82 ient transfers, contributes to the spread of nosocomial infections and investigate how network struct

83 ad to better informed decision making around nosocomial infections and other time-dependent exposures

84 Acinetobacter baumannii frequently causes nosocomial infections and outbreaks.

85 1 are associated with a higher incidence of nosocomial infections and seem to be major actors of sep

86 intervention to help reduce the incidence of nosocomial infections and sepsis postburn.

87 blood transfusions had a higher incidence of nosocomial infections and sepsis, and the amount of bloo

88 Many nosocomial infections arise from gastrointestinal coloni

89 ted readmissions consistently had index-stay nosocomial infections as a predictor for HE, renal/metab

90 ts with advanced cirrhosis and prevention of nosocomial infections could reduce this burden.

91 ys (interquartile range, 2-11 d) and 21% had nosocomial infections diagnosed after status epilepticus

92 The incidence of nosocomial infections due to carbapenem-resistant Klebsi

93 logy, risk factors, and impact on outcome of nosocomial infections during extracorporeal membrane oxy

94 est KP activity, both at baseline, developed nosocomial infections during follow-up.

95 nosocomial transmission; 24% of patients had nosocomial infections from an unknown source; and 43% we

96 excess length of stay (LOS) attributable to nosocomial infections have failed to address time-varyin

97 B. animalis subsp. lactis failed to prevent nosocomial infections in an acute-setting pediatric hosp

98 The incidence of nosocomial infections in children in developed countries

99 occus faecalis is frequently responsible for nosocomial infections in humans and represents one of th

100 cterium animalis subsp. lactis in preventing nosocomial infections in the acute hospital setting.

101 Fungi cause serious nosocomial infections including candidiasis and aspergil

102 ces and transmission routes in patients with nosocomial infections not linked to other patients and a

103 Nosocomial infections of Elizabethkingia species can hav

104 Nosocomial infections pose a significant threat to patie

105 " pathogen which is a major cause of serious nosocomial infections such as bacteremia, sepsis, and en

106 Furthermore, nosocomial infections such as invasive aspergillosis and

107 for Disease Control and Prevention National Nosocomial Infections Surveillance.

108 diabetes have increased recurrent, chronic, nosocomial infections that worsen the long-term morbidit

109 The prevalence of nosocomial infections was detected during 28 days of ICU

110 n into account that the overall incidence of nosocomial infections was lower than expected.

111 The number of patients with nosocomial infections was significantly reduced in the f

112 Nosocomial infections were defined as infections that oc

113 of </= 20 TIPS/year, variceal bleeding, and nosocomial infections were independent risk factors for

114 Nosocomial infections with Clostridium difficile are on

115 BACKGROUND & AIMS: Nosocomial infections with Clostridium difficile present

116 , known to cause both community-acquired and nosocomial infections worldwide.

117 ulitis are projected to cause more than 9000 nosocomial infections, 1000 to 5000 Clostridium difficil

118 frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature,

119 Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all a

120 nterobacter, genera commonly associated with nosocomial infections, dominate the preterm infant gut m

121 bacterial species that are common sources of nosocomial infections, Escherichia coli and Staphylococc

122 tors underlying the outcome of P. aeruginosa nosocomial infections, including aspects related to the

123 Enterococcus faecium is a common cause of nosocomial infections, of which infective endocarditis i

124 ginosa is among the leading causes of severe nosocomial infections, particularly affecting critically

125 nt-line antibiotic used for the treatment of nosocomial infections, particularly those caused by meth

126 is the fourth most common cause of systemic nosocomial infections, posing a significant risk in immu

127 sed percentages of blood MDSCs had increased nosocomial infections, prolonged intensive care unit sta

128 rging pathogen that causes a wide variety of nosocomial infections, spreads rapidly within hospitals,

129 vironmental commensal and a leading cause of nosocomial infections, which are often caused by multire

130 rial biofilms responsible for persistent and nosocomial infections.

131 opportunistic pathogens and major causes of nosocomial infections.

132 ity of pathogens to evolve in the context of nosocomial infections.

133 ida species are one of the leading causes of nosocomial infections.

134 ticularly high-risk population to intestinal nosocomial infections.

135 s responsible for approximately one-third of nosocomial infections.

136 ere associated with subsequent occurrence of nosocomial infections.

137 dysfunction responsible for poor outcome and nosocomial infections.

138 cost-effective mechanism to monitor emerging nosocomial infections.

139 testinal tract (GIT) and an agent of serious nosocomial infections.

140 ndependently associated with higher risk for nosocomial infections.

141 a L. pneumophila population responsible for nosocomial infections.

142 ingly been recognized as a major pathogen in nosocomial infections.

143 evices, it has emerged as a leading cause of nosocomial infections.

144 h, sexually transmitted infections and major nosocomial infections.

145 ve bacterium responsible for a wide range of nosocomial infections.

146 responsible for up to 10% of gram-negative, nosocomial infections.

147 56 inpatients, 63% were classified as having nosocomial infections.

148 A) which is one of the most common causes of nosocomial infections.

149 shock and correlated to adverse outcomes or nosocomial infections.

150 ic fibrosis patients and is a major agent of nosocomial infections.

151 ents were used to estimate the proportion of nosocomial infections.

152 V infections were more heterogeneous than in nosocomial infections.

153 sociated with an increased susceptibility to nosocomial infections.

154 terococcus faecium (VRE) is a major cause of nosocomial infections.

155 ounds, which is one of the causes of serious nosocomial infections.

156 inetobacter baumannii causes a wide range of nosocomial infections.

157 cystic fibrosis (CF), and a leading cause of nosocomial infections.

158 h, sexually transmitted infections and major nosocomial infections.

159 iated with cirrhosis severity, diabetes, and nosocomial infections; close monitoring of patients with

160 infection (CDI) is the most common cause of nosocomial infectious diarrhea and may result in severe

161 stridium difficile is the principal cause of nosocomial infectious diarrhea worldwide.

162 pproach is imperative to control and prevent nosocomial influenza in health-care settings.

163 Common nosocomial isolates are dominated by single lineages of

164 ations, rather than acquisition of resistant nosocomial isolates.

165 ments were found at a higher frequency among nosocomial isolates.

166 This case study confirms that the typically nosocomial lineage (E-MRSA15) can transmit within commun

167 further performed whole-genome sequencing of nosocomial MDRPa strains to evaluate genotypic relations

168 acquired, 56% healthcare associated, and 20% nosocomial) met study criteria.

169 h recently emerged as global pathogens, with nosocomial mortality rates reaching 19-54%.

170 the study was to estimate the proportion of nosocomial NoV infections among inpatients testing posit

171 Nosocomial NoV infections were associated with age >/=60

172 e species within the Acinetobacter genus are nosocomial opportunistic pathogens of increasing relevan

173 ion of genotype 1a before 1965 suggests that nosocomial or iatrogenic factors rather than past sporad

174 Patients with CPVC presented more nosocomial origin (32% vs 20%, P = .014), more septic sh

175 tes belonging to ST14 were isolated during a nosocomial outbreak from 6 patients.

176 ase of reinfection was observed in a Belgian nosocomial outbreak involving 3 patients and 2 health ca

177 nd HSV, the viruses commonly associated with nosocomial outbreaks in eye care.

178 tent sporadic cases, community clusters, and nosocomial outbreaks of MERS-CoV continue to occur.

179 Health-care workers have been implicated in nosocomial outbreaks of Staphylococcus aureus, but the d

180 rtionately, many cases of HCV infection from nosocomial outbreaks were attributable to provider tampe

181 he hypervirulent clade 2 are responsible for nosocomial outbreaks worldwide.

182 ct the health of patients by preventing such nosocomial outbreaks.

183 The nosocomial pathogen Acinetobacter baumannii is a frequen

184 tributes to the broad drug resistance of the nosocomial pathogen Acinetobacter baumannii.

185 Acinetobacter baumannii is a nosocomial pathogen capable of causing a range of diseas

186 Acinetobacter baumannii is a common nosocomial pathogen capable of causing severe diseases a

187 lecular transacylase) from the opportunistic nosocomial pathogen Enterococcus faecalis synthesizes a

188 Here we focus on the important nosocomial pathogen Enterococcus faecium in a hospital s

189 Acinetobacter baumannii is a nosocomial pathogen for which the limited treatment opti

190 dium difficile is the most commonly reported nosocomial pathogen in the United States and is an urgen

191 n important role in driving the evolution of nosocomial pathogen populations.

192 as maltophilia is an emerging, opportunistic nosocomial pathogen that can cause severe disease in imm

193 r baumannii is a Gram-negative opportunistic nosocomial pathogen that causes pneumonia and soft tissu

194 tobacter baumannii is a globally distributed nosocomial pathogen that has gained interest due to its

195 Acinetobacter baumannii is an emerging, nosocomial pathogen that is poorly characterized due to

196 ococcus aureus (MRSA) has emerged as a major nosocomial pathogen that is widespread in both health-ca

197 Clostridium difficile is a major nosocomial pathogen that produces two exotoxins, TcdA an

198 Staphylococcus aureus (MRSA) is a primarily nosocomial pathogen that, in recent years, has increasin

199 Acinetobacter baumannii is a prevalent nosocomial pathogen with a high incidence of multidrug r

200 Acinetobacter baumannii (Ab) is a nosocomial pathogen with one of the highest rates of mul

201 nterococcus faecalis (VREfs) is an important nosocomial pathogen(1,2).

202 dium difficile is a significant concern as a nosocomial pathogen, and genetic tools are important whe

203 infections, due to Staphylococcus aureus, a nosocomial pathogen, is still in its nascent stages.

204 bacter baumannii has emerged as an important nosocomial pathogen, particularly for patients in intens

205 ia is a ubiquitous bacterium and an emerging nosocomial pathogen.

206 to study the mode of action of this emerging nosocomial pathogen.

207 maltophilia is an emerging opportunistic and nosocomial pathogen.

208 nterococcus faecalis (VREfs) is an important nosocomial pathogen1,2.

209 antimicrobial activity against twelve common nosocomial pathogenic microorganisms including Staphyloc

210 ations with a broader coverage against these nosocomial pathogens and that the evaluated proteins are

211 stridium difficile is one of the most common nosocomial pathogens and the cause of pseudomembranous c

212 Enterococci have emerged as important nosocomial pathogens due to their resistance to the most

213 tobacter baumannii-calcoaceticus complex are nosocomial pathogens frequently causing multidrug-resist

214 ability of providers to match treatment with nosocomial pathogens is unknown.

215 s to accurately match antibiotic coverage to nosocomial pathogens remains low.

216 plays a crucial role in the transmission of nosocomial pathogens such as MRSA.

217 baumannii (A. baumannii) strains are common nosocomial pathogens that can cause infections and can e

218 stani surfaces, respectively, include common nosocomial pathogens, rare opportunistic pathogens, and

219 and environmental persistence genes between nosocomial pathogens.

220 lay an important role in the transmission of nosocomial pathogens.

221 logical surveillance of multi-drug resistant nosocomial pathogens.

222 ost important and problematic, opportunistic nosocomial pathogens.

223 l surfaces may contribute to transmission of nosocomial pathogens.

224 biotics for pneumonia despite no increase in nosocomial pathogens.

225 truction and greater risk of colonization by nosocomial pathogens.

226 tibiotics for patients with risk factors for nosocomial pathogens.

227 can help elucidate the transmission route of nosocomial pathogens.

228 g that these Enterobacteriaceae are emerging nosocomial pathogens.

229 case of severe falciparum malaria following nosocomial Plasmodium falciparum transmission in nonende

230 The burden of nosocomial Pneumocystis infections in transplantation un

231 e undergoing mechanical ventilation, and had nosocomial pneumonia (either ventilator-associated pneum

232 Adults with nosocomial pneumonia (including ventilator-associated pn

233 alternative to carbapenems in patients with nosocomial pneumonia (including ventilator-associated pn

234 ion (block size four), stratified by type of nosocomial pneumonia and age (<65 years vs >=65 years),

235 Nosocomial pneumonia due to antimicrobial-resistant path

236 Patients with nosocomial pneumonia exhibit elevated levels of neurotox

237 d well tolerated treatment for Gram-negative nosocomial pneumonia in mechanically ventilated patients

238 natants or CSF from patients with or without nosocomial pneumonia indicated that endothelium-derived

239 Nosocomial pneumonia is commonly associated with antimic

240 ty of ceftazidime-avibactam in patients with nosocomial pneumonia, including ventilator-associated pn

241 Klebsiella pneumoniae, a chief cause of nosocomial pneumonia, is a versatile and commonly multid

242 tiple clinical descriptions of S. marcescens nosocomial pneumonia, little is known regarding the mech

243 on-inferior to meropenem in the treatment of nosocomial pneumonia.

244 t of hospital-related infections, especially nosocomial pneumonia.

245 viders caring for hospitalized patients with nosocomial pneumonia.

246 MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.

247 illin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia.

248 an etiologic agent of community-acquired and nosocomial pneumonia.

249 ions between MRSA virulence and mortality in nosocomial pneumonia.

250 ression syndrome and to decrease the rate of nosocomial pneumonia.

251 ed amikacin for critically ill patients with nosocomial pneumonia.

252 sus meropenem for treatment of Gram-negative nosocomial pneumonia.

253 ost important enteropathogen involved in gut nosocomial post-antibiotic infections.

254 ents are susceptible to infections caused by nosocomial respiratory pathogens at least in part becaus

255 ration sequencing, was used to investigate a nosocomial respiratory syncytial virus-B (RSV-B) outbrea

256 Nosocomial respiratory virus outbreaks represent serious

257 more effective prevention strategies to curb nosocomial respiratory virus outbreaks.

258 Of the latter, 27.6% had a nosocomial RV infection in PreVP, and 19.3% in PostVP.

259 Overall, the proportion of nosocomial RV infections increased from 5.5% in PreVP to

260 In older patients, heightened awareness of nosocomial RV infections is warranted.

261 uired S aureus infections, and 132 (17%) had nosocomial S aureus infections.

262 healthcare-associated SAB, and 7% (9/136) in nosocomial SAB.

263 We also detected a likely nosocomial SARI cluster associated with a novel picobirn

264 fective than ceftazidime in the treatment of nosocomial SBP (86.7 vs. 25%; P < 0.001).

265 Patients with cirrhosis and nosocomial SBP were randomized to receive meropenem (1 g

266 ed a broader spectrum antibiotic regimen for nosocomial SBP, according to the high rate of bacteria r

267 eneration cephalosporins in the treatment of nosocomial SBP.

268 azidime as empirical antibiotic treatment of nosocomial SBP.

269 mycin versus ceftazidime in the treatment of nosocomial SBP.

270 redictor of 90-day survival in patients with nosocomial SBP.

271 primarily infects critically ill patients in nosocomial settings.

272 Prevention of nosocomial spread currently focuses on spread by hand an

273 Tracking the nosocomial spread of resistant bacteria is critical to i

274 Nosocomial spread was suspected solely because of the hi

275 the risk for worsened surgical outcomes and nosocomial spread.

276 and inexpensive intervention that may reduce nosocomial spread.

277 otic eradication treatment failure; however, nosocomial strain transmission was associated with estab

278 What is the relative importance of nosocomial transmission compared with community-acquired

279 ox cases exported from Africa, and a related nosocomial transmission event in the UK became the first

280 Recently, the significance of nosocomial transmission has been challenged by screening

281 The risk of nosocomial transmission is high for patients and staff a

282 Preventing measles virus nosocomial transmission likely decreases measles mortali

283 d hospital system may have contributed to no nosocomial transmission occurring during the treatment o

284 Nosocomial transmission of influenza A virus (InfA) infe

285 iple norovirus strains with extensive onward nosocomial transmission of norovirus in a pediatric hosp

286 of whole viral genome sequencing to identify nosocomial transmission of varicella-zoster virus with f

287 by estimating the effects of antibiotics on nosocomial transmission risk, comparing competing hypoth

288 care workers; among the health care workers, nosocomial transmission was implicated in 12 patients (3

289 In addition, findings indicated that nosocomial transmission within health facilities helped

290 rveillance, increased zoonotic transmission, nosocomial transmission, and changes in viral transmissi

291 ew patients who were known contacts, ongoing nosocomial transmission, and persistent delays in detect

292 ion needs to be balanced against the risk of nosocomial transmission.

293 the same otherwise rare alleles, suggesting nosocomial transmission.

294 patients, thereby reducing the potential for nosocomial transmission.

295 gically unchanged viruses in connection with nosocomial transmission.

296 and/or their direct environment, supporting nosocomial transmission.

297 d be considered when investigating norovirus nosocomial transmission.

298 norovirus sequences were linked, suggesting nosocomial transmission; 24% of patients had nosocomial

299 c in C. elegans, and a similar mutant of the nosocomial V583 isolate showed significantly attenuated

300 ility of whole-genome sequencing in defining nosocomial VREfm transmission.